# US 2012/0251550 A1 · Crystalline anti-hTNFalpha antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251550 A1
- Document ID: US20120251550A1
- Status: Published application
- Kind: A1
- Application number: 13/225,281
- Filed: 2011-09-02
- Published: 2012-10-04
- Earliest claimed: 2006-10-27
- Assignees: Abbott Biotechnology Ltd.
- Inventors: David W. Borhani; Wolfgang Fraunhofer; Hans-Juergen Krause; Anette Koenigsdorfer; Gerhard Winter; Stefan Gottschalk
- Web page: https://patentgrep.com/patent/US20120251550A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/00: General protective or antinoxious agents
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.

## Claims

### Claim 1

A batch crystallization method for crystallizing an anti-hTNFalpha antibody, comprising the steps of:
(a) providing an aqueous solution of said antibody in admixture with an inorganic phosphate salt as crystallization agent; and
(b) incubating said aqueous crystallization mixture until crystals of said antibody are formed.

### Claim 2 (depends on 1)

The crystallization method according to claim 1, wherein the pH of said aqueous crystallization mixture is in the range of about pH 3 to about 5.

### Claim 3 (depends on 1)

The crystallization method according to claim 1, wherein said aqueous crystallization mixture contains a buffer.

### Claim 4 (depends on 3)

The crystallization method according to claim 3, wherein said buffer comprises an acetate buffer.

### Claim 5 (depends on 4)

The crystallization method according to claim 4, wherein the buffer comprises sodium acetate.

### Claim 6 (depends on 3)

The crystallization method according to claim 3, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M.

### Claim 7 (depends on 4)

The crystallization method according to claim 4, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M.

### Claim 8 (depends on 5)

The crystallization method according to claim 5, wherein the buffer concentration in said aqueous crystallization mixture is about 0 M to about 0.5 M.

### Claim 9 (depends on 1)

The crystallization method according to claim 1, wherein the phosphate salt is a hydrogenphosphate salt.

### Claim 10 (depends on 1)

The crystallization method according to claim 1, wherein the phosphate salt is an alkali metal salt, or a mixture of at least two different alkali metal salts.

### Claim 11 (depends on 1)

The crystallization method according to claim 1, wherein the phosphate salt concentration in the crystallization mixture is in the range of about 1 to 6 M.

### Claim 12 (depends on 11)

The crystallization method according to claim 11, wherein the salt concentration in the crystallization mixture is in the range of about 1.0 to 3.0 M.

### Claim 13 (depends on 1)

The crystallization method according to claim 1, wherein at least one of the following additional crystallization conditions are met:
a) incubation is performed for between about 1 hour to about 60 days;
b) incubation is performed at a temperature between about 4° C. and about 37° C.;
c) the antibody concentration is in the range of about 0.5 to about 100 mg/ml.

### Claim 14 (depends on 13)

The crystallization method according to claim 13, further comprising the step of drying said crystals.

### Claim 15 (depends on 13)

The crystallization method according to claim 13, further comprising the step of exchanging the crystallization mother liquor with a different buffer.

### Claim 16 (depends on 13)

The crystallization method according to claim 13, wherein the batch comprises a batch volume in the range of about 1 ml to about 20,000 liters.

### Claim 17 (depends on 1)

A crystal of an anti-hTNFalpha antibody, obtainable by the crystallization method according to claim 1.

### Claim 18

A crystal of an anti-hTNFalpha antibody, with the proviso that said antibody is not INFLIXIMAB.

### Claim 19 (depends on 17)

The crystal according to claim 17 having a needle-like morphology with a maximum length I of about 2-500 μm and an l/d ratio of about 3 to 30.

### Claim 20 (depends on 18)

The crystal according to claim 18 having a needle-like morphology with a maximum length I of about 2-500 μm and an l/d ratio of about 3 to 30.

### Claim 21 (depends on 17)

The crystal according to claim 17, wherein said antibody is a polyclonal anti-body or a monoclonal antibody.

### Claim 22 (depends on 21)

The crystal according to claim 21, wherein said antibody is selected from the group consisting of: chimeric antibodies, humanized antibodies, non-glycosylated antibodies, human antibodies and mouse antibodies.

### Claim 23 (depends on 21)

The crystal according to claim 21, wherein said antibody is an IgG antibody.

### Claim 24 (depends on 21)

The crystal according to claim 21, wherein said antibody is selected from the group consisting of: IgG1, IgG2, IgG3 and IgG4, antibodies.

### Claim 25 (depends on 24)

The crystal according to claim 24, wherein said antibody is an anti-human TNFalpha antibody of the group IgG1.

### Claim 26 (depends on 25)

The crystal according to claim 25, prepared from an isolated human antibody, that dissociates from hTNFalpha with a Kd of 1×10−8 M or less and a Ka rate constant of 1×10−3 s−1 or less, both determined by surface plasmon resonance, and neutralizes hTNFalpha cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10−7 M or less.

### Claim 27 (depends on 25)

The crystal according to claim 25, prepared from an isolated human antibody with the following characteristics: a) dissociates from human TNFalpha with a Koff rate constant of 1×10−3 s−1 or less, as determined by surface plasmon resonance; b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.

### Claim 28 (depends on 25)

The crystal according to claim 25, prepared from an isolated human antibody with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 29 (depends on 28)

The crystal according to claim 28, prepared from the antibody D2E7.

### Claim 30 (depends on 17)

A pharmaceutical composition comprising: (a) crystals of an anti-hTNFalpha antibody according to claim 17, and (b) at least one pharmaceutical excipient;
which composition is provided in as solid, semisolid or liquid formulation, each formulation containing said antibody in crystalline form.

### Claim 31 (depends on 17)

A pharmaceutical composition comprising: (a) crystals of an anti-hTNFalpha antibody according to claim 17, and (b) at least one pharmaceutical excipient, which embeds or encapsulates crystals of said antibody.

### Claim 32 (depends on 29)

The composition according to claim 29, wherein said composition has an antibody concentration greater than about 1 mg/ml.

### Claim 33 (depends on 30)

The composition according to claim 30, wherein said composition has an antibody concentration greater than about 200 mg/ml.

### Claim 34 (depends on 29)

The composition according to claim 29, wherein said excipient comprises at least one polymeric optionally biodegradable carrier or at least one oil or lipid carrier.

### Claim 35 (depends on 34)

The composition according to claim 34, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-glycolic acid) or PLGA, poly (β-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl)methacrylamide, poly[(organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof.

### Claim 36 (depends on 17)

An injectable liquid composition comprising anti-hTNFalpha antibody crystals according to claim 17 and having an antibody concentration in the range of about 10 to 400 mg/ml.

### Claim 37 (depends on 17)

A crystal slurry comprising anti-hTNFalpha antibody crystals according to claim 17, having a antibody concentration greater than about 100 mg/ml.

### Claim 38 (depends on 17)

A method for treating a mammal comprising the step of administering to the mammal an effective amount of antibody anti-hTNFalpha crystals according to claim 17.

### Claim 39 (depends on 30)

A method for treating a mammal comprising the step of administering to the mammal an effective amount of the composition according to claim 30.

### Claim 40 (depends on 35)

The method according to claim 35, wherein the composition is administered by parenteral route, oral route, or by injection.

### Claim 41 (depends on 17)

A method of treating a TNFalpha-related disorder in a subject, which method comprises administering a therapeutically effective amount of antibody crystals according to claim 17.

### Claim 42 (depends on 39)

The method of claim 39, wherein said TNFalpha-related disorder is selected from the group consisting of
an autoimmune disease, in particular rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and gouty arthritis, an allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis and nephrotic syndrome; an infectious disease, trans-plant rejection or graft-versus-host disease, malignancy, pulmonary disorder, intestinal disorder, cardiac disorder, inflammatory bone disorders, bone resorption disease, alcoholic hepatitis, viral hepatitis, fulminant hepatitis, coagulation disturbances, burns, reperfusion injury, keloid formation, scar tissue formation, pyrexia, periodontal disease, obesity and radiation toxicity; a spondyloarthropathy, a pulmonary disorder, a coronary disorder, a metabolic disorder, anemia, pain, a hepatic disorder, a skin disorder, a nail disorder, or vasculitis, Behcet's disease, ankylosing spondylitis, asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), restenosis, diabetes, anemia, pain, a Crohn's disease-related disorder, juvenile rheumatoid arthritis (JRA), a hepatitis C virus infection, psoriasis, psoriatic arthritis, and chronic plaque psoriasis, age-related cachexia, Alzheimer's disease, brain edema, inflammatory brain injury, chronic fatigue syndrome, dermatomyositis, drug reactions, edema in and/or around the spinal cord, familial periodic fevers, Felty's syndrome, fibrosis, glomerulonephritides (e.g. post-streptococcal glomerulonephritis or IgA nephropathy), loosening of prostheses, microscopic polyangiitis, mixed connective tissue disorder, multiple myeloma, cancer and cachexia, multiple organ disorder, myelo dysplastic syndrome, orchitism osteolysis, pancreatitis, including acute, chronic, and pancreatic abscess, periodontal disease polymyositis, progressive renal failure, pseudogout, pyoderma gangrenosum, relapsing polychondritis, rheumatic heart disease, sarcoidosis, sclerosing cholangitis, stroke, thoracoabdominal aortic aneurysm repair (TAAA), TNF receptor associated periodic syndrome (TRAPS), symptoms related to Yellow Fever vaccination, inflammatory diseases associated with the ear, chronic ear inflammation, or pediatric ear inflammation, uveitis, sciatica, prostatitis, endometriosis, choroidal neovascularization, lupus, Sjogren's syndrome, and wet macular degeneration.

### Claim 43 (depends on 17)

The use of anti-hTNFalpha antibody crystals according to claim 17 for preparing a pharmaceutical composition for treating a TNFalpha-related disease.

### Claim 44 (depends on 17)

Anti-hTNFalpha antibody crystals according to claim 17 for use in medicine.
